Table 2

Frequency of and time to HAART associated toxic complications by initiating regimen

Condition

Stavudine (N = 8497)

Other drugs (N = 543)


Peripheral neuropathy

Frequency

1454 (17.1)*

61 (11.2)*

Time to diagnosis

6.7 (3.8-111.8)

5.1 (3.1-11.7)


Symptomatic hyperlactataemia

Frequency

487 (5.7)*

12 (2.2)*

Time to diagnosis

14.5 (10.6-20.9)

11.6 (8.7-19.4)


Lactic Acidosis

Frequency

214 (2.5)

7 (1.3)

Time to diagnosis

10.8 (9.0-13.5)

11.2 (9.0-13.5)


Pancreatitis

Frequency

14 (0.2)

1 (0.2)

Time to diagnosis

10.4(4.0-13.0)

8.3 (8.3-8.3)


Lipoatrophy

Frequency

616 (7.3)**

25 (4.6) **

Time to diagnosis

17.0 (11.4-23.1)

15.0 (10.5-24.8)


Hypertension

Frequency

167 (2.0)

9.7 (4.6-18.4)**

Time to diagnosis

17 (3.1)

(9.3-30.5)**


Diabetes

Frequency

28 (0.3)

1 (0.2)

Time to diagnosis

22.4 (12.5-28.1)

9.0 (9.0-9.0)


Dyslipidaemia

Frequency

109 (1.3)

9(1.7)

Time to diagnosis

24.6 (17.4-34.0)

19.1 (15.3-26.1)


Data is given as n (%) for prevalence and median (IQR) for time to diagnosis;

*p < 0.005, **p < 0.05 versus group receiving stavudine.

Menezes et al. BMC Infectious Diseases 2011 11:244   doi:10.1186/1471-2334-11-244

Open Data